Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1747641 | 0.85 | CA2 (0.36) | CA2CA12CA9CA1CA4 | |
| SCHEMBL23030081 | 0.80 | CA1 (0.37) | CA2CA12CA9CA1CA4 | |
| SCHEMBL24857595 | 0.74 | TSHR (0.34) | CA2CA12CA9CA1RIPK2 | |
| SCHEMBL24857596 | 0.74 | LMNA (0.37) | CA2CA9CA1RIPK2ALOX5 | |
| SCHEMBL308829 | 0.71 | GPR3 (0.41) | CA2CA12CA9CA1 | |
| SCHEMBL30430615 | 0.71 | GPR3 (0.41) | CA2CA12CA9CA1 | |
| SCHEMBL18805435 | 0.69 | CYP2A6 (0.35) | RIPK2ALDH1A1 | |
| SCHEMBL23030082 | 0.68 | CA1 (0.35) | CA2CA12CA9CA1CA4 | |
| SCHEMBL1326395 | 0.66 | S100A4 (0.46) | CA2CA12CA9CA1CA4 | |
| SCHEMBL29726026 | 0.66 | S100A4 (0.46) | CA2CA12CA9CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112409385-B | Azaaryl compounds and uses thereof | 上海青煜医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-4019521-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021032004-A9 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
| WO-2021032004-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | EZH2, EED, SUZ12 | CA2 3791/4885CA12 3102/4885CA9 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.